**Vrijdag 14 februari 2020**

|  |  |
| --- | --- |
| 15.30 – 16.00 | **Ontvangst en registratie** |
|  | **Dagpanel:*** Dr Erik Cornel (uroloog perifeer)
* Dr Jorg Oddens (uroloog academie)
* Dr Niven Mehra (oncoloog academie)
* Dr Franchette van de Berkmortel (oncoloog perifeer)
* Dr Hanneke Meijer (radiotherapeut)

Het dagpanel draagt zorg voor de multidisciplinaire discussie gedurende het hele programma. Tevens zullen zij de verschillende onderwerpen introduceren o.b.v. hun expertise gebied**Dag Chairs**: dr. Erik Cornel & dr. Jorg Oddens |
| 16:00 – 16:15 | **Welkom en opening****Chairs:** dr. Erik Cornel & dr. Jorg Oddens- Toelichting op het programma en de selectie van de sessies uit  het ASCO-GU programma. - Toelichting op het interactieve live programma met San Francisco |
| 16:15 – 17:45 | **Onderwerp: prostaatcarcinoom****Chairs:** dr. Erik Cornel & dr. Jorg Oddens**General Session: Localized Prostate Cancer: Individualizing Diagnosis, Staging, and Treatment****Introductie door urologen****[20 min]****Optimal Use of mp-MRI in the Management of Localized Prostate Cancer**Ivo G. Schoots, MD, PhDErasmus University Medical Center**[20 min]** **PSMA PET: Who Should Undergo Advanced Imaging in the Current Era?**Jeremie Calais, MDUCLA**Introductie door dr. Hanneke Meijer en uroloog****[20 min] Debate: Integration of Systemic and Localized Treatment for High-Risk Localized Prostate Cancer**Juanita Crook, MD, FRCPCUniversity of British ColumbiaRadiation OncologistJames Andrew Eastham, MDMemorial Sloan Kettering Cancer CenterSurgeon**[30 min] Discussie & casus** **Casus dr. Erik Cornel: Hoog-risico prostaatcarcinoom met zeer kleine metastase op PSMA-scan** |
| 17:45 – 18:00 | **Pauze** |
| 18:00 – 19:05 | **Onderwerp: prostaatcarcinoom****Chairs:** dr. Erik Cornel & dr. Jorg Oddens**Oral Abstract Session A: Prostate Cancer****Introductie door oncoloog****[10 min] Abstract 82: Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).**First Author: Neeraj Agarwal, MD**[10 min] Abstract 162: Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.**First Author: Anis Hamid, MBBS**[30 min] Discussie & casus** **Casus dr. Niven Mehra: patiënt met mHSPC met high volume bone, recent progressief op abiraterone in eerste lijn CRPC, met positieve familie-anamnese.** |
| 19:05 – 20:00 | **Diner** |
| 20.00 – 20.15 | **Terugkeer naar zaal voor live sessie** |
| 20:15 – 20:45 | **Live sessie met San Francisco****Nederland:**Chairs: **dr. Erik Cornel & dr. Jorg Oddens & Hanneke Meijer****San Francisco:****Onderwerp: Optimal Integration of Systemic and Localized Treatment for High-Risk Localized Prostate Cancer****Invited speaker: dr. Juanita Crook -** University of British Columbia**Co-speakers:** **Prof. dr. Winald Gerritsen** - Radboudumc, Nijmegen**Dr. Andre Bergman** - NKI-AvL, Amsterdam |
| 20.45-21.30 | **Onderwerp: prostaatcarcinoom****Chairs:** dr. Erik Cornel & dr. Jorg Oddens**General Session: Targeted Therapy in the Context of Low-Volume Metastatic Prostate Cancer****Introductie dr. Hanneke Meijer en uroloog****[25 min]** **Metastasis-Directed Therapy: Are We Changing Outcomes That Matter?**Neha Vapiwala, MDUniversity of Pennsylvania**[10 min] Abstract 10: Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.**First author: Piet Ost**[10 min] Discussie** |
| 21.30 | **Afsluiting & drankje** |

**Zaterdag 15 februari 2020**

|  |  |
| --- | --- |
|  | **Dagpanel:*** Dr Erik Cornel (uroloog perifeer)
* Dr Jorg Oddens (uroloog academie)
* Dr Niven Mehra (oncoloog academie)
* Dr Franchette van de Berkmortel (oncoloog perifeer)
* Dr Hannele Meijer (radiotherapeut)

Het dagpanel draagt zorg voor de multidisciplinaire discussie gedurende het hele programma. Tevens zullen zij de verschillende onderwerpen introduceren o.b.v. hun expertise gebied**Dag Chairs**: dr. Franchette van den Berkmortel en dr. Niven Mehra |
| 8:15 – 8:30 | **Welkom en opening dag 2****Chairs:** dr. Franchette van den Berkmortel en dr. Niven Mehra |
| 8:30 – 9:30 | **Onderwerp: prostaatcarcinoom****Chairs:** dr. Franchette van den Berkmortel en dr. Niven Mehra**General Session: Current Controversies in the Treatment of Prostate Cancer****Introductie dr Niven Mehra****[25 min] Contemporary Clinical Impact of Genetic and Genomic Testing in Prostate Cancer**Elena Castro, MD, PhDSpanish National Cancer Research Centre**Rapid Abstract Session A: Prostate Cancer****Introductie oncoloog en dr. Hanneke Meijer****[10 min] Abstract 14: Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial.**First Author: Hannah L. Rush**[10 min] Abstract 325: Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial.**First Author: David P. Dearnaley, MD, FRCR**[10 min] Discussie / casuïstiek** |
| 9:30 – 10:00 | **Bekijken opgenomen interview uit San Francisco****Introductie oncologen*****Biomarkers for renal cell carcinoma*****Invited speaker: dr. Martin Voss –** Memorial Sloan Kettering Cancer Center, New York**[10 min] Aanvullende discussie** |
| 10:00 – 10:30 | **Pauze** |
| 10:30 – 11:30 | **Onderwerp: zeldzame urologische tumoren****Chairs:** dr. Franchette van den Berkmortel en dr. Niven Mehra**General session: Current Developments in Rare Urologic Malignancies****Introductie oncologen/urologen****[15 min] Chemotherapy-Sparing Management Strategies for Early-Stage Germ Cell Tumors**Clint Cary, MD, MPHIndiana University School of Medicine**[15 min] Management of Advanced Poor-Risk Germ Cell Tumors**Christian K. Kollmannsberger, MDBC Cancer–Vancouver Cancer Centre**Oral Abstract Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers****[10 min] Abstract 386: Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.**First Author: Joerg Beyer, MD**Rapid Abstract Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers****[10 min] Abstract 388: Evaluation of the oncologic benefit of adjunctive surgery at time of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).**First Author: Tim Nestler, MD, MD**[10 min] Discussie** |
| 11:30 – 12:45 | **Onderwerp: urotheelcarcinoom****Chairs:** dr. Franchette van den Berkmortel en dr. Niven Mehra**Introductie oncologen****General session: Confronting Obstacles in Treating Non-Muscle-Invasive and Upper Tract Urothelial Carcinoma****[20 min] Upper Tract Disease: Topical Therapy, Systemic Therapy**Jean H. Hoffman-Censits, MDSidney Kimmel Comprehensive Cancer Center at Johns Hopkins**[10 min] Abstract 436: Treatment of high-grade non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: Results of the phase III clinical trial (NIMBUS).**First author: Marc-Oliver Grimm**Rapid Abstract Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers****[10 min] Abstract 442: Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial.**First Author: Stephen A. Boorjian, MD**[15 min] Discussie / casuïstiek** |
| 12:30 – 13:30 | **Lunch** |
| 13:30 – 14:00 | **Bekijken opgenomen interview uit San Francisco****Introductie urologen****Novel Approaches to First-Line Intravesical Therapy****Invited speaker:** Prof. Dr. Shahrokh Shariat, Medical University of Vienna**Interviewer:** Dr. André Bergman – NKI-AVL, Amsterdam**[10 min] Discussie** |
| 14:00 – 15:15  | **Onderwerp: urotheelcarcinoom** **Chairs:** dr. Franchette van den Berkmortel en dr. Niven Mehra**Casus dr. Hanneke Meijer: patiënt met blaascarcinoom met klinisch complete respons op neo-adjuvante chemotherapie** **Oral Abstract Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers****[10 min] Abstract 438: Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE).**First Author: Syed A. Hussain, MD**General session: Risk Stratification and Management of High-Risk Urothelial Carcinoma****[10 min] Abstract 437: Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses.**First Author: Stephane Culine**Rapid Abstract Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers****[10 min] Abstract 441: Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.**First Author: Jonathan E. Rosenberg, MD**[30 min] Discussie & casus****Casus dr. Jorg Oddens: 80-jarige man met invasieve blaastumor** |
| 15:15 – 15:45 | **Wrap-up en afsluiting** |

Reserves:

Doordat het congres in SF plaats vindt met een tijdsverschil van 9 uur, is het niet altijd mogelijk om de sessie die op het programma staan werkelijk te bekijken, omdat de spreker geen toestemming geeft of de kwaliteit van de opnames niet toereikend zijn.

Daarom is er een reserve lijst opgenomen om eventueel gaten in het programma op te vangen.

**Dr. Fons van den Berg**, die zich intensief heeft beziggehouden met het samenstellen van het programma zal in SF aanwezig zijn om de verschillende sessies te beoordelen. Mochten er sessies uitvallen kan hij aangeven wat de vervangende sessies zouden moeten worden vanuit het oogpunt van de Nederlandse praktijk.

*Donderdagsessies*

**General session: Localized Prostate Cancer: Individualizing Diagnosis, Staging, and Treatment**

**[20 min]****Individualized Approaches to Treatment in Localized Prostate Cancer**

Adam S. Kibel, MD

Brigham and Women's Hospital/ Harvard Medical School

**[10 min] Abstract 9: A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.**

First author: Frederic Pouliot

**General Session: Targeted Therapy in the Context of Low-Volume Metastatic Prostate Cancer**

**[25 min] Biologic and Clinical Rationale for Treatment of the Primary in Low-Volume Metastatic Disease**

Phuoc T. Tran, MD, PhD

Johns Hopkins School of Medicine

**[25 min]** **Beyond Standard Imaging: Defining Extent of Disease Using Novel Approaches**

Richard J. Lee, MD, PhD

Massachusetts General Hospital Cancer Center

**Oral Abstract Session A: Prostate Cancer**

**[10 min] Abstract 276: Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.**

First Author: Felix Y. Feng, MD, BA

**General session: Current Controversies in the Treatment of Prostate Cancer**

**[25 min] Implementation of Novel Tools in the Active Surveillance Pathway**

Laurence Klotz, MD

Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto

**[10 min] Abstract 8: Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes.**

First author: Himisha Beltran, MD

**Rapid Abstract Session A: Prostate Cancer**

**[10 min] Abstract 15: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.**

First Author: Julie Nicole Graff, MD

**[10 min] Abstract 16: Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.**

First Author: Karim Fizazi, MD, PhD

**[10 min] Abstract 17: The effect of deep AR suppression with enzalutamide or apalutamide on endogenous glucocorticoids: Implications for adverse effects and development of combination therapies.**

First Author: Nima Sharifi, MD

*Vrijdagsessies*

**Rapid Abstract Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers**

**[10 min] Abstract 426: Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).**

First Author: Joseph Jacob, MD

**[10 min] Abstract 440: Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial.**

First Author: Petros Grivas, MD, PhD

**General session: Confronting Obstacles in Treating Non-Muscle-Invasive and Upper Tract Urothelial Carcinoma**

**[20 min]****Management Strategies in the Face of the BCG Shortage**

Sam S. Chang, MD, MBA

Vanderbilt University School of Medicine

**[20 min] Novel Approaches to First-Line Intravesical Therapy**

Shahrokh F. Shariat, MD

Medical University of Vienna

**[20 min] Options for BCG Refractory Disease**

Wassim Kassouf, FRCS, MD

McGill University Health Centre

**Oral Abstract Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers**

**[10 min] Abstract 387: The SEMITEP trial : De-escalating chemotherapy in low-volume metastatic seminoma based on early FDG-PET.**

First Author: Yohann Loriot, MD, PhD

**[10 min] Abstract 439: Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.**

First Author: Shilpa Gupta, MD

**General session: Risk Stratification and Management of High-Risk Urothelial Carcinoma**

**Opportunities and Limitations of Genomics in Everyday Practice**

**[12 min]****Subtyping**

William Y. Kim, MD

UNC Lineberger Comprehensive Cancer Center

**[12 min] Circulating Tumor Cells**

David T. Miyamoto, MD, PhD

Massachusetts General Hospital/ Harvard Medical School

**[12 min] Circulating Tumor DNA**

Alexander William Wyatt, PhD

Vancouver Prostate Centre, University of British Columbia

**[12 min]** **Adjuvant Options in High-Risk Disease After Primary Intervention**

Matt D. Galsky, MD, FASCO

Mount Sinai School of Medicine

**[12 min] New Standards in First-Line Therapy for Advanced Disease**

Cora N. Sternberg, MD, FACP

Weill Cornell Medicine

**CASE DISCUSSIONS (evt. in te zetten als casuïstiek, wel vooraf screenen op toepasbaarheid in NL)**

*Donderdag*

**Case-Based Session**

**Challenging Cases in Prostate Cancer**

Scott E. Eggener, MD

University of Chicago

*Urologist*

Valérie Fonteyne MD, PhD

Ghent University Hospital

*Radiotherapist*

Celestia S. Higano, MD, FACP

University of Washington and Fred Hutchinson Cancer Research Center

*Medical Oncologist*

Thomas Hope, MD

UCSF Helen Diller Family Comprehensive Cancer Center

*Radiologist*

*Vrijdag*

**Case-Based Session**

**Practicing Beyond Clinical Trial Data: Real-World Challenges in Urothelial Carcinoma**

Brian Christopher Baumann, MD

Washington University in St. Louis

*Radiation Oncologist*

Andrea B. Apolo, MD

National Cancer Institute

*Medical Oncologist*

Alison J. Birtle, MRCP, FRCR, MD

Lancashire Teaching Hospitals NHS Foundation Trust

*Clinical Oncologist*

Nicholas D. James, PhD, MBBS, FRCP

University of Birmingham and Queen Elizabeth Hospital

*Clinical Oncologist*